COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.25% | 31.82% | 45.22% | 42.11% | 39.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.25% | 31.82% | 45.22% | 42.11% | 39.69% |
| Cost of Revenue | -33.84% | -25.31% | -17.85% | -19.58% | 271.13% |
| Gross Profit | 184.87% | 898.42% | 913.78% | 570.78% | -68.08% |
| SG&A Expenses | 46.85% | 91.93% | 188.09% | 194.86% | 15.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 66.39% | 131.63% | 270.12% | 307.25% | -25.10% |
| Operating Income | -241.02% | -359.63% | -3,095.15% | -1,573.50% | 66.34% |
| Income Before Tax | -356.36% | -1,267.33% | -3,272.92% | -1,712.82% | 83.22% |
| Income Tax Expenses | 157.51% | 154.83% | 132.38% | 107.01% | -501.60% |
| Earnings from Continuing Operations | -1,200.70% | -4,160.78% | -1,811.79% | -814.71% | 93.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,200.70% | -4,160.78% | -1,811.79% | -814.71% | 93.54% |
| EBIT | -241.02% | -359.63% | -3,095.15% | -1,573.50% | 66.34% |
| EBITDA | -811.91% | -899.55% | -1,223.73% | -564.61% | 87.49% |
| EPS Basic | -272.96% | -112.35% | -118.42% | -163.02% | 91.13% |
| Normalized Basic EPS | -126.79% | -23.90% | -33.98% | -69.40% | 80.39% |
| EPS Diluted | -272.49% | -112.23% | -118.28% | -162.82% | 91.12% |
| Normalized Diluted EPS | -126.79% | -23.90% | -33.98% | -69.40% | 80.39% |
| Average Basic Shares Outstanding | 15.71% | 39.18% | 34.16% | 19.19% | 78.41% |
| Average Diluted Shares Outstanding | 15.71% | 39.18% | 34.16% | 19.19% | 78.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |